Daniel J. Schuster

Daniel J. Schuster

Auto-generated profile, based on publicly available information

Daniel J. Schuster

Departments of Surgery and Integrative Immunobiology, Center for Human Systems Immunology, Duke University, Durham, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 November 2022 in JCI Insight
Verified
Journal Article
Open access
PDF file
DSDaniel J. Schuster
Daniel J. Schuster
SKShelly Karuna
Shelly Karuna
CBCaroline Brackett
Caroline Brackett
MWMartina S. Wesley
Martina S. Wesley
SLShuying S. Li
Shuying S. Li
KSKelly E. Seaton
Kelly E. Seaton
People living with HIV-1 (PLWH) exhibit more rapid antibody decline following routine immunization and elevated baseline chronic inflammation than people without HIV-1 (PWOH), indicating potential for diminished humoral immunity during SARS-CoV-2 infection. Conflicting reports have emerged on the ability of PLWH to maintain humoral protection against SARS-CoV-2 coinfection during convalescence. It is unknown whether peak COVID-19 severity, along with HIV-1 infection status, associates with the quality and quantity of humoral immunity following recovery. Using a cross-sectional observational cohort from the United States and Peru, adults were enrolled 1–10 weeks after SARS-CoV-2 infection diagnosis or symptom resolution. Serum antibodies were analyzed for SARS-CoV-2–specific response rates, binding magnitudes, ACE2 receptor blocking, and antibody-dependent cellular phagocytosis. Overall, (a) PLWH exhibited a trend toward decreased magnitude of SARS-CoV-2–specific antibodies, despite modestly increased overall response rates when compared with PWOH; (b) PLWH recovered from symptomatic outpatient COVID-19 had comparatively diminished immune responses; and (c) PLWH lacked a corresponding increase in SARS-CoV-2 antibodies with increased COVID-19 severity when asymptomatic versus symptomatic outpatient disease was compared.

1 January 2025 in Science Translational Medicine
Verified
Journal Article
Closed access
IAImran J. Anwar
Imran J. Anwar
IDIsabel DeLaura
Isabel DeLaura
JLJoseph M Ladowski
Joseph M Ladowski
DSDavide Schiliró
Davide Schiliró
QGQimeng Gao
Qimeng Gao
SKStuart Knechtle
Stuart Knechtle
Current desensitization and maintenance immunosuppression regimens for kidney transplantation in sensitized individuals show limited ability to control the posttransplant humoral response, resulting in high rates of antibody-mediated rejection (ABMR) and graft failure. Here, we showed that anti-CD154 monoclonal antibody (mAb)–based immunosuppression more effectively controlled allograft rejection and humoral rebound in a highly sensitized nonhuman primate kidney transplantation model compared with tacrolimus-based standard-of-care (SOC) immunosuppression. Desensitization with an anti-CD154 mAb (5C8) and a proteasome inhibitor led to decreased donor-specific antibodies (DSAs) and disruption of lymph node germinal centers with reduction of proliferating, memory, and class-switched B cells as well as T follicular helper cells. After transplant, the nonhuman primates maintained on 5C8-based immunosuppression had significantly better survival compared with those maintained on SOC immunosuppression (135.2 days versus 32.8 days, P = 0.013). The 5C8-treated group demonstrated better suppression of DSAs after transplant, more robust suppression of B cell populations, and better induction of regulatory T cells. Fewer infectious and welfare complications, including viral reactivation and weight loss, were also observed with 5C8-based immunosuppression compared with SOC immunosuppression. Therefore, anti-CD154 mAbs may improve kidney transplant outcomes through better control of posttransplant immune responses. The superior efficacy of anti-CD154 mAb–based immunosuppression over tacrolimus-based SOC seen in this highly sensitized NHP transplant model suggests that anti-CD154 mAbs could potentially be used to desensitize and treat highly sensitized patients receiving kidney transplantation.

6 October 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
NMNonhlanhla N. Mkhize
Nonhlanhla N. Mkhize
BZBo Zhang
Bo Zhang
CBCaroline Brackett
Caroline Brackett
PEPeter James Elyanu
Peter James Elyanu
ATAsa Tapley
Asa Tapley
PGPeter B. Gilbert
Peter B. Gilbert
People with HIV (PWH) are understudied in COVID-19 vaccine trials, leaving knowledge gaps on whether the identified immune correlates of protection also hold in PWH. CoVPN 3008 (NCT05168813) enrolled predominantly PWH and reported lower COVID-19 incidence for a Hybrid vs. Vaccine Group (baseline SARS-CoV-2-positive and one mRNA-1273 dose vs. negative and two doses). Using case-cohort sampling, antibody markers at enrolment (M0) and four weeks post-final vaccination (Peak) are assessed as immune correlates of COVID-19. For the Hybrid Group [n = 287 (195 PWH)], all M0 markers inversely correlate with COVID-19 through 230 days post-Peak, with 50% inhibitory dilution BA.4/5 neutralizing antibody titer (nAb-ID50 BA.4/5) the strongest and only independent correlate (HR per 10-fold increase=0.46, 95% CI 0.28, 0.75; P = 0.002). For the Vaccine Group [n = 115 (86 PWH)], Peak nAb-ID50 BA.4/5 correlates with reduced COVID-19 risk (1.9%, 1.1%, and 0.3% at titers 10, 100, and 1000 AU/ml) through 92, but not 165, days post-Peak. Using multivariable Cox analysis of binding and nAb, nAb titers predict COVID-19 in PWH. Two doses of a 100-µg Ancestral strain mRNA vaccine in baseline-SARS-CoV-2-negative individuals elicit sufficient cross-reacting Omicron antibodies to reduce COVID-19 incidence for 90 days post-Peak, but viral evolution and waning antibodies abrogate this protection thereafter.

23 April 2025 in Communications Medicine
Verified
Journal Article
Open access
PDF file
DMDieter Mielke
Dieter Mielke
SLShuying Sue Li
Shuying Sue Li
DSDaniel J. Schuster
Daniel J. Schuster
XLXiaohong Li
Xiaohong Li
JHJiani Hu
Jiani Hu
GFGuido Ferrari
Guido Ferrari
Background: SARS-CoV-2 infection results in greater disease severity among immunocompromised individuals compared to healthy individuals. However, there is conflicting information about the impact of chronic HIV infection on immune responses to SARS-CoV-2 infection and vaccination. Method: We used a combination of machine learning approaches and network analysis to explore 56 immune markers and comprehensively profile humoral and cellular immunity in a cross-sectional observational cohort of people without HIV (PWOH; n = 216) and people living with HIV (PLWH; n = 43) who recovered from SARS-CoV-2 infection (13–131 days since SARS-COV-2 diagnosis) early in the pandemic. Results: PLWH recovered from symptomatic outpatient COVID-19 exhibit lower humoral and B cell responses to SARS-CoV-2 vs. PWOH but, surprisingly, both symptomatic outpatient and hospitalized PLWH have higher anti-endemic coronavirus antibody responses compared to PWOH counterparts and asymptomatic PLWH. The latter observation suggests that this was not strictly due to broadly elevated levels of anti-endemic coronavirus antibodies in PLWH. Moreover, correlation-based analysis reveals that while different compartments of the immune response to SARS-CoV-2 infection are positively correlated in PWOH recovered from symptomatic outpatient COVID-19, these correlations are weaker in PLWH. Conclusion: Our analyses reveal significant differences in the coordinated immune responses elicited by infection in PLWH compared to PWOH.

9 March 2026 in iScience
Verified
Journal Article
Open access
DSDaniel J. Schuster
Daniel J. Schuster
SLShuying S. Li
Shuying S. Li
DMDieter Mielke
Dieter Mielke
KSKelly E. Seaton
Kelly E. Seaton
CBCaroline Brackett
Caroline Brackett
GTGeorgia Tomaras
Georgia Tomaras
SARS-CoV-2 acquisition induces a spectrum of COVID-19 disease severity and duration among people. Prolonged viral antigen shedding (PVS) is defined as when a person tests positive by direct antigen tests performed a minimum of 21 days apart. It is unclear why some people exhibit delayed SARS-CoV-2 viral antigen clearance. In this cross-sectional observational study enrolling vaccine naive adults from the USA and Peru following recovery from SARS-CoV-2 acquisition, we examined a suite of blood-derived immune measures to understand differences between participants with PVS (n = 36) and without PVS (non-PVS, n = 223). While PVS participants demonstrated lower overall SARS-CoV-2-specific antibody magnitudes, over-representation analysis revealed that immune feature magnitude alone could not fully explain cohort differences. Hierarchical clustering and network analyses identified more highly coordinated antibody responses, T cell activation, and Fc-mediated function among non-PVS compared to PVS participants. These findings link control of viral antigen shedding to a coordinated immune response.